Renal cell carcinoma appears to be resistant to conventional treatment modalities. Introduction of advanced techniques of molecular biology into practice helped to establish the potent role of membrane receptors for growth factors, especially the component with activity of thyrosine kinases, in growth, proliferation, invasion and formation of metastatic lesions. One of the most investigated and advanced agents in clinical trials is sorafenib (Nexavar). The article is a short review of literature regarding the drug with special attention paid to clinical data.